A Retrospective Analysis of Clinical Features and Treatment of the Inflammatory Bowel Disease in China

References

• Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Roda G, Chien NS, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22. doi:10.1038/s41572-020-0156-2
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517. doi:10.1053/j.gastro.2004.01.063
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54e42; quiz e30. doi:10.1053/j.gastro.2011.10.001
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727. doi:10.1038/nrgastro.2015.150
   PubMed Web of Science ®Google Scholar
• Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013;28(7):1148–1153. doi:10.1111/jgh.12164
   PubMed Web of Science ®Google Scholar
• Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis. 2016;22(8):1954–1960. doi:10.1097/MIB.0000000000000846
   PubMed Web of Science ®Google Scholar
• Cohn HM, Dave M, Loftus EV Jr. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1301–1315. doi:10.1097/MIB.0000000000001199
   PubMed Web of Science ®Google Scholar
• Lonnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L. IBD and health-related quality of life – discovering the true impact. J Crohns Colitis. 2014;8(10):1281–1286. doi:10.1016/j.crohns.2014.03.005
   PubMed Web of Science ®Google Scholar
• Ekbom A. The changing epidemiology of IBD. In: Cohen RD, editor. Inflammatory Bowel Disease. Springer Science + Business Media; 2011:17–26.
   Google Scholar
• Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y). 2012;8(1):29–38.
   PubMedGoogle Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670. doi:10.1093/ecco-jcc/jjx008
   PubMed Web of Science ®Google Scholar
• Olivera PA, Zuily S, Kotze PG, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(12):857–873. doi:10.1038/s41575-021-00492-8
   PubMed Web of Science ®Google Scholar
• Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489–526. doi:10.1007/s00535-021-01784-1
   PubMed Web of Science ®Google Scholar
• Jones JL, Tse F, Carroll MW, et al. Canadian association of gastroenterology clinical practice guideline for immunizations in patients with Inflammatory Bowel Disease (IBD)-Part 2: Inactivated vaccines. J Can Assoc Gastroenterol. 2021;4(4):e72–e91. doi:10.1093/jcag/gwab016
   PubMedGoogle Scholar
• Benchimol EI, Tse F, Carroll MW, et al. Canadian association of gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)-Part 1: Live vaccines. J Can Assoc Gastroenterol. 2021;4(4):e59–e71. doi:10.1093/jcag/gwab015
   PubMedGoogle Scholar
• Group IB, Chinese Medical Association. Beijing: Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). Chin J Dig. 2018;38(5):292–311.
   Google Scholar
• Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western Countries. Gastroenterology. 2018;155(4):1079–1089 e1073. doi:10.1053/j.gastro.2018.06.043
   PubMed Web of Science ®Google Scholar
• Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology. 2016;150(7):1561–1567 e1561. doi:10.1053/j.gastro.2016.02.041
   PubMed Web of Science ®Google Scholar
• Ortizo R, Lee SY, Nguyen ET, Jamal MM, Bechtold MM, Nguyen DL. Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol. 2017;29(9):1064–1070. doi:10.1097/MEG.0000000000000915
   PubMed Web of Science ®Google Scholar
• Duricova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos PL. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis. 2014;8(11):1351–1361. doi:10.1016/j.crohns.2014.05.006
   PubMed Web of Science ®Google Scholar
• Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982;12(4):351–359. doi:10.1111/j.1365-2362.1982.tb02244.x
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV Jr., Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(8):707–712. doi:10.1097/01.MIB.0000173271.18319.53
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423–432. doi:10.1053/j.gastro.2007.05.029
   PubMed Web of Science ®Google Scholar
• Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19(10):1079–1087. doi:10.1111/j.1365-2036.2004.01945.x
   PubMed Web of Science ®Google Scholar
• Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007;13(1):24–32. doi:10.1002/ibd.20047
   PubMed Web of Science ®Google Scholar
• Joossens S, Daperno M, Shums Z, et al. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem. 2004;50(8):1422–1425. doi:10.1373/clinchem.2004.032318
   PubMed Web of Science ®Google Scholar
• Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7(1):8–15. doi:10.1097/00054725-200102000-00002
   PubMed Web of Science ®Google Scholar
• Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;10:CD000067. doi:10.1002/14651858.CD000067.pub3
   PubMed Web of Science ®Google Scholar
• Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N, Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD006884. doi:10.1002/14651858.CD006884.pub3
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–885. doi:10.1056/NEJMoa030815
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn’s disease over 15 years. Gut. 2012;61(8):1140–1145. doi:10.1136/gutjnl-2011-301971
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8(10):1179–1207. doi:10.1016/j.crohns.2014.04.005
   PubMed Web of Science ®Google Scholar
• Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–1471. doi:10.4065/81.11.1462
   PubMed Web of Science ®Google Scholar
• Vuitton L, Koch S, Peyrin-Biroulet L. Preventing postoperative recurrence in Crohn’s disease: what does the future hold? Drugs. 2013;73(16):1749–1759. doi:10.1007/s40265-013-0128-x
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–447. doi:10.1016/j.cgh.2012.10.020
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608. doi:10.1056/NEJMoa020888
   PubMed Web of Science ®Google Scholar
• Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012;35(6):625–633. doi:10.1111/j.1365-2036.2012.05002.x
   PubMed Web of Science ®Google Scholar